Cencora (COR) – Investment Analysts’ Recent Ratings Updates

Cencora (NYSE: COR) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – Cencora had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Cencora was given a new $392.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – Cencora had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Cencora is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $400.00 price target on the stock.
• 12/8/2025 – Cencora had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Cencora was upgraded by analysts at Barclays PLC to a “strong-buy” rating.
• 12/1/2025 – Cencora was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 11/28/2025 – Cencora was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/25/2025 – Cencora had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Cencora had its price target raised by analysts at JPMorgan Chase & Co. from $344.00 to $417.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – Cencora had its price target raised by analysts at Wells Fargo & Company from $354.00 to $405.00. They now have an “overweight” rating on the stock.
• 11/10/2025 – Cencora had its price target raised by analysts at TD Cowen from $350.00 to $400.00. They now have a “buy” rating on the stock.
• 11/8/2025 – Cencora was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/7/2025 – Cencora had its price target raised by analysts at UBS Group AG from $380.00 to $415.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Cencora was given a new $400.00 price target on by analysts at Evercore ISI. They now have an “outperform” rating on the stock.
• 11/6/2025 – Cencora had its price target raised by analysts at Robert W. Baird from $355.00 to $395.00. They now have an “outperform” rating on the stock.
• 11/6/2025 – Cencora had its price target raised by analysts at Mizuho from $340.00 to $380.00. They now have an “outperform” rating on the stock.
• 10/30/2025 – Cencora had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/30/2025 – Cencora had its price target raised by analysts at Mizuho from $334.00 to $340.00. They now have an “outperform” rating on the stock.
• 10/27/2025 – Cencora had its price target raised by analysts at UBS Group AG from $350.00 to $380.00. They now have a “buy” rating on the stock.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

Insider Buying and Selling at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is currently owned by insiders.

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.